Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 31.43%, which has investors questioning if this is right time ...

Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...

Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders ...

Quite a few insiders have dramatically grown their holdings in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) over the past 12 months. An insider's optimism about the company's prospects is a positive ...

Jan 29 (Reuters) - Inhibikase Therapeutics (IKT.O), opens new tab said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients ...

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...